126 related articles for article (PubMed ID: 36099749)
21. β-Adrenergics enhance brain extraction of levodopa.
Uc EY; Dienel GA; Cruz NF; Harik SI
Mov Disord; 2002 Jan; 17(1):54-9. PubMed ID: 11835439
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in vitro BBB models.
Liu Q; Hou J; Chen X; Liu G; Zhang D; Sun H; Zhang J
PLoS One; 2014; 9(7):e102442. PubMed ID: 25036090
[TBL] [Abstract][Full Text] [Related]
23. L-DOPA is incorporated into brain proteins of patients treated for Parkinson's disease, inducing toxicity in human neuroblastoma cells in vitro.
Chan SW; Dunlop RA; Rowe A; Double KL; Rodgers KJ
Exp Neurol; 2012 Nov; 238(1):29-37. PubMed ID: 22001774
[TBL] [Abstract][Full Text] [Related]
24. Pinostrobin Exerts Neuroprotective Actions in Neurotoxin-Induced Parkinson's Disease Models through Nrf2 Induction.
Li C; Tang B; Feng Y; Tang F; Pui-Man Hoi M; Su Z; Ming-Yuen Lee S
J Agric Food Chem; 2018 Aug; 66(31):8307-8318. PubMed ID: 29961319
[TBL] [Abstract][Full Text] [Related]
25. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-DOPA.
Martignoni E; Blandini F; Godi L; Desideri S; Pacchetti C; Mancini F; Nappi G
Free Radic Biol Med; 1999 Aug; 27(3-4):428-37. PubMed ID: 10468218
[TBL] [Abstract][Full Text] [Related]
26. Neuroprotective effects of dimerumic acid and deferricoprogen from Monascus purpureus NTU 568-fermented rice against 6-hydroxydopamine-induced oxidative stress and apoptosis in differentiated pheochromocytoma PC-12 cells.
Tseng WT; Hsu YW; Pan TM
Pharm Biol; 2016 Aug; 54(8):1434-44. PubMed ID: 26794209
[TBL] [Abstract][Full Text] [Related]
27. Novel anti-apoptotic L-DOPA precursors SuperDopa and SuperDopamide as potential neuroprotective agents for halting/delaying progression of Parkinson's disease.
Wiesen T; Atlas D
Cell Death Dis; 2022 Mar; 13(3):227. PubMed ID: 35277478
[TBL] [Abstract][Full Text] [Related]
28. Sulforaphane prevents PC12 cells from oxidative damage via the Nrf2 pathway.
Bao B; Zhang MQ; Chen ZY; Wu XB; Xia ZB; Chai JY; Yin XP
Mol Med Rep; 2019 Jun; 19(6):4890-4896. PubMed ID: 31059012
[TBL] [Abstract][Full Text] [Related]
29. No increased chromosomal damage in L-DOPA-treated patients with Parkinson's disease: a pilot study.
Oli RG; Fazeli G; Kuhn W; Walitza S; Gerlach M; Stopper H
J Neural Transm (Vienna); 2010 Jun; 117(6):737-46. PubMed ID: 20401731
[TBL] [Abstract][Full Text] [Related]
30. Blood-brain barrier permeability in Parkinson's disease patients with and without dyskinesia.
Fujita K; Peng S; Ma Y; Tang CC; Hellman M; Feigin A; Eidelberg D; Dhawan V
J Neurol; 2021 Jun; 268(6):2246-2255. PubMed ID: 33502551
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
[TBL] [Abstract][Full Text] [Related]
32. Ameliorative effects of docosahexaenoic acid on the toxicity induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in cultured rat hepatocytes.
Turkez H; Geyikoglu F; Yousef MI
Toxicol Ind Health; 2016 Jun; 32(6):1074-85. PubMed ID: 25187318
[TBL] [Abstract][Full Text] [Related]
33. Effect of l-DOPA on local field potential relationship between the pedunculopontine nucleus and primary motor cortex in a rat model of Parkinson's disease.
Geng X; Wang X; Xie J; Zhang X; Wang X; Hou Y; Lei C; Li M; Han H; Yao X; Zhang Q; Wang M
Behav Brain Res; 2016 Dec; 315():1-9. PubMed ID: 27515286
[TBL] [Abstract][Full Text] [Related]
34. L-dopa increases α-synuclein DNA methylation in Parkinson's disease patients in vivo and in vitro.
Schmitt I; Kaut O; Khazneh H; deBoni L; Ahmad A; Berg D; Klein C; Fröhlich H; Wüllner U
Mov Disord; 2015 Nov; 30(13):1794-801. PubMed ID: 26173746
[TBL] [Abstract][Full Text] [Related]
35. Treatment of Parkinson's disease in Zebrafish model with a berberine derivative capable of crossing blood brain barrier, targeting mitochondria, and convenient for bioimaging experiments.
Wang L; Sheng W; Tan Z; Ren Q; Wang R; Stoika R; Liu X; Liu K; Shang X; Jin M
Comp Biochem Physiol C Toxicol Pharmacol; 2021 Nov; 249():109151. PubMed ID: 34343700
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic effect of hydrogen sulfide-releasing L-Dopa derivative ACS84 on 6-OHDA-induced Parkinson's disease rat model.
Xie L; Hu LF; Teo XQ; Tiong CX; Tazzari V; Sparatore A; Del Soldato P; Dawe GS; Bian JS
PLoS One; 2013; 8(4):e60200. PubMed ID: 23573240
[TBL] [Abstract][Full Text] [Related]
37.
Hu S; Wu Y; Zhao B; Hu H; Zhu B; Sun Z; Li P; Du S
Molecules; 2018 Oct; 23(11):. PubMed ID: 30373188
[TBL] [Abstract][Full Text] [Related]
38. Protective Effects and Mechanisms of Procyanidins on Parkinson's Disease In Vivo and In Vitro.
Chen J; Chen Y; Zheng Y; Zhao J; Yu H; Zhu J; Li D
Molecules; 2021 Sep; 26(18):. PubMed ID: 34577027
[TBL] [Abstract][Full Text] [Related]
39. Α-aryl-N-alkyl nitrones, as potential agents for stroke treatment: synthesis, theoretical calculations, antioxidant, anti-inflammatory, neuroprotective, and brain-blood barrier permeability properties.
Chioua M; Sucunza D; Soriano E; Hadjipavlou-Litina D; Alcázar A; Ayuso I; Oset-Gasque MJ; González MP; Monjas L; Rodríguez-Franco MI; Marco-Contelles J; Samadi A
J Med Chem; 2012 Jan; 55(1):153-68. PubMed ID: 22126405
[TBL] [Abstract][Full Text] [Related]
40. Deferoxamine and Curcumin Loaded Nanocarriers Protect Against Rotenone-Induced Neurotoxicity.
Mursaleen L; Somavarapu S; Zariwala MG
J Parkinsons Dis; 2020; 10(1):99-111. PubMed ID: 31868679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
